H.R. 1051 · 119th Congress

To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.

Stage
In committee
Introduced
2025-02-06
Latest action
2025-02-06 · Introduced in House

Subjects

Health
Prescription drugs
Drug safety, medical device, and laboratory regulation